NASDAQ:ADRO - Aduro BioTech Stock Price, Forecast & News

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

Aduro BioTech Inc (NASDAQ:ADRO) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.03. The biotechnology company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $4.55 million. Aduro BioTech had a negative net margin of 544.94% and a negative return on equity of 78.64%. View Aduro BioTech's Earnings History.

Aduro BioTech is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Aduro BioTech.

7 brokers have issued 1-year target prices for Aduro BioTech's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate Aduro BioTech's stock price to reach $5.50 in the next year. This suggests a possible upside of 50.7% from the stock's current price. View Analyst Price Targets for Aduro BioTech.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aduro BioTech.

Media coverage about ADRO stock has trended somewhat negative on Sunday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aduro BioTech earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Aduro BioTech.

Some companies that are related to Aduro BioTech include Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Odonate Therapeutics (ODT), NextCure (NXTC), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Phathom Pharmaceuticals (PHAT), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Dermira (DERM) and Myovant Sciences (MYOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include Regulus Therapeutics (RGLS), EXACT Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), PTC Therapeutics (PTCT), Anavex Life Sciences (AVXL), MDxHealth (MXDHF) and Juno Therapeutics (JUNO).

(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aduro BioTech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.76%), Baillie Gifford & Co. (5.26%), Ikarian Capital LLC (2.28%), State Street Corp (1.49%), Geode Capital Management LLC (1.08%) and Goldman Sachs Group Inc. (0.96%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Institutional Ownership Trends for Aduro BioTech.

ADRO stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., State Street Corp, Assenagon Asset Management S.A. and Bank of America Corp DE. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.

ADRO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ikarian Capital LLC, Goldman Sachs Group Inc., Acadian Asset Management LLC, Jacobs Levy Equity Management Inc., J. Goldman & Co LP, Oxford Asset Management LLP and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Aduro BioTech.

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADRO stock can currently be purchased for approximately $3.65.

Aduro BioTech has a market capitalization of $293.86 million and generates $15.09 million in revenue each year. The biotechnology company earns $-95,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe.View Additional Information About Aduro BioTech.

The official website for Aduro BioTech is http://www.aduro.com/.

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]